Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
| dc.contributor.author | Ozguroglu, Mustafa | |
| dc.contributor.author | Beuzeboc, Philippe | |
| dc.contributor.author | Massard, Christophe | |
| dc.contributor.author | Rouge, Thibault De La Motte | |
| dc.contributor.author | Delanoy, Nicolas | |
| dc.contributor.author | Elaidi, Reza-Thierry | |
| dc.contributor.author | Oudard, Stephane | |
| dc.contributor.author | Angelergues, Antoine | |
| dc.contributor.author | Maillet, Denis | |
| dc.contributor.author | Flechon, Aude | |
| dc.contributor.author | Mercier, Florence | |
| dc.contributor.author | Guillot, Aline | |
| dc.contributor.author | Le Moulec, Sylvestre | |
| dc.contributor.author | Gravis, Gwenaelle | |
| dc.date.accessioned | 2021-03-06T12:21:52Z | |
| dc.date.available | 2021-03-06T12:21:52Z | |
| dc.identifier.citation | Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc P., Massard C., et al., "Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).", Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32 | |
| dc.identifier.other | av_f375db24-f90e-4d4d-ade3-3ccccaf78fc9 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/159660 | |
| dc.identifier.uri | https://doi.org/10.1200/jco.2014.32.4_suppl.282 | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). | |
| dc.type | Bildiri | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 32 | |
| dc.contributor.firstauthorID | 143688 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]